Your browser doesn't support javascript.
loading
Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.
Goudsmit, Ben F J; Putter, Hein; Tushuizen, Maarten E; de Boer, Jan; Vogelaar, Serge; Alwayn, I P J; van Hoek, Bart; Braat, Andries E.
Afiliação
  • Goudsmit BFJ; Division of Transplantation, Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
  • Putter H; Eurotransplant International Foundation, Leiden, The Netherlands.
  • Tushuizen ME; Division of Transplantation, Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
  • de Boer J; Department of Biomedical Data Sciences, Leiden, The Netherlands.
  • Vogelaar S; Division of Transplantation, Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Alwayn IPJ; Eurotransplant International Foundation, Leiden, The Netherlands.
  • van Hoek B; Eurotransplant International Foundation, Leiden, The Netherlands.
  • Braat AE; Division of Transplantation, Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Am J Transplant ; 21(1): 229-240, 2021 01.
Article em En | MEDLINE | ID: mdl-32529758
ABSTRACT
The MELD score is used in the Eurotransplant (ET) region to allocate liver grafts. Hyponatremia in cirrhotic patients is an important predictor of death but is not incorporated in MELD. This study investigated the performance of the MELD-Na score for the ET region. All adult patients with chronic liver disease on the ET liver transplantation waiting list (WL) allocated through lab MELD scores were included. The MELD-corrected effect of serum sodium (Na) concentration at listing on the 90-day WL mortality was calculated using Cox regression. The MELD-Na performance was assessed with c-indices, calibration per decile and Brier scores. The reclassification from MELD to MELD-Na score was calculated to estimate the impact of MELD-Na-based allocation in the ET region. For the 5223 included patients, the risk of 90-day WL death was 2.9 times higher for hyponatremic patients. The MELD-Na had a significantly higher c-index of 0.847 (SE 0.007) and more accurate 90-day mortality prediction compared to MELD (Brier score of 0.059 vs 0.061). It was estimated that using MELD-Na would reduce WL mortality by 4.9%. The MELD-Na score yielded improved prediction of 90-day WL mortality in the ET region and using MELD-Na for liver allocation will very likely reduce WL mortality.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Doença Hepática Terminal Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Doença Hepática Terminal Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article